BRISTOL MYERS SQUIBB CO
For the period ended Dec 31, 2023. Filed Feb 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 13, 2024
BMY$62.80+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
PART IAInformation about our Executive Officers
PART IA
Information about our Executive Officers
Listed below is information on our executive officers as of February 13, 2024. Executive officers are elected by the Board of Directors for an initial term, which continues until the first Board meeting following the next Annual Meeting of Shareholders, and thereafter, are elected for a one-year term or until their successors have been elected. Executive officers serve at the discretion of the Board of Directors.
| Name and Current Position | Age | Employment History for the Past 5 Years |
|---|---|---|
| Christopher Boerner, Ph.D.Chief Executive OfficerMember of the Leadership Team | 53 | 2015 to 2017 – President and Head of U.S. Commercial2017 to 2018 – President and Head, International Markets2018 to 2023 – Executive Vice President, Chief Commercialization Officer2023 to 2023 – Executive Vice President, Chief Operating Officer2023 to present – Chief Executive Officer |
| Giovanni Caforio, M.D.Executive Chairman of the BoardMember of the Leadership Team | 59 | 2015 to 2017 – Chief Executive Officer and Director of the Company2017 to 2023 – Chairman of the Board and Chief Executive Officer2023 to present – Executive Chairman of the Board |
| David V. ElkinsExecutive Vice President and Chief Financial OfficerMember of the Leadership Team | 55 | 2014 to 2017 – Group Vice President and Chief Financial Officer, Consumer and Consumer Medicines, Johnson & Johnson2017 to 2018 – Worldwide Vice President and Chief Financial Officer, Consumer Products, Medical Development and Corporate Functions, Johnson & Johnson2018 to 2019 – Chief Financial Officer, Celgene Corporation2019 to present – Executive Vice President and Chief Financial Officer |
| Cari GallmanExecutive Vice President, Corporate AffairsMember of the Leadership Team | 44 | 2015 to 2018 – Senior Counsel, US Legal2018 to 2019 – Assistant General Counsel, Oncology Legal 2019 to 2021 – Vice President, Assistant General Counsel, Worldwide Oncology 2021 to 2023 – Senior Vice President, Chief Compliance Officer2023 to present – Executive Vice President, Corporate Affairs |
| Sharon GreenleesSenior Vice President, Corporate Controller | 52 | 2016 to 2018 – Vice President of Investor Relations, AbbVie Inc.2018 to 2020 – Head of Pricing, U.S. Commercial, AbbVie Inc.2020 to 2021 – Head of Supply Chain Finance, AbbVie Inc.2021 to 2022 – Vice President and Controller, R&D Finance and Operations, AbbVie Inc.2022 to present – Senior Vice President, Corporate Controller |
| Samit Hirawat, M.D.Executive Vice President, Chief Medical Officer, Head of DevelopmentMember of the Leadership Team | 55 | 2017 to 2019 – Executive Vice President, Head of Oncology Development, Novartis2019 to 2023 – Executive Vice President, Chief Medical Officer, Global Drug Development2023 to present – Executive Vice President, Chief Medical Officer, Head of Development |
| Lynelle HochPresident, Cell Therapy OrganizationMember of the Leadership Team | 51 | 2016 to 2019– Vice President, Immuno-Oncology Marketing2019 to 2021 – General Manager, Ireland & UK, Major Markets2021 to 2023 – Senior Vice President, Global Cell Therapy Franchise Lead2023 to present – President, Cell Therapy Organization |
| Adam LenkowskyExecutive Vice President, Chief Commercialization OfficerMember of the Leadership Team | 52 | 2016 to 2019 – Head of US Oncology2019 to 2022 – Senior Vice President, General Manager of U.S. Oncology, Immunology & Cardiovascular2022 to 2023 Senior Vice President, Head of Major Markets2023 to present – Executive Vice President, Chief Commercialization Officer |
| Sandra Leung Executive Vice President, General CounselMember of the Leadership Team | 63 | 2015 to present – Executive Vice President, General Counsel |
| Greg MeyersExecutive Vice President, Chief Digital and Technology OfficerMember of the Leadership Team | 51 | 2014 to 2018 – Corporate Vice President and Chief Information Officer, Motorola Solutions2018 to 2022 – Group Chief Information and Digital Officer, Syngenta Group2022 to present – Executive Vice President, Chief Digital and Technology Officer |
| Robert Plenge, M.D., Ph.D.Executive Vice President, Chief Research Officer, Head of ResearchMember of the Leadership Team | 53 | 2017 to 2019 – Vice President Inflammation and Immunology, Thematic Center of Excellence Unit, Celgene Corporation2019 to 2021 – Senior Vice President, Immunology, Cardiovascular & Fibrosis, Thematic Research Center2021 to 2023 – Senior Vice President, Immunology, Cardiovascular & Fibrosis, Thematic Research Center, and Head of Translational Medicine2023 to 2023 – Senior Vice President and Head of Discovery and Translational Sciences 2023 to present – Executive Vice President, Chief Research Officer, Head of Research |
| Amanda PooleExecutive Vice President, Chief Human Resources OfficerMember of the Leadership Team | 49 | 2017 to 2019 – Vice President, Head of Human Resources, Global Product Development & Supply2019 to 2020 – Vice President, Head of BMS/Celgene Integration2020 to 2022 – Senior Vice President, Head of Human Resources, Commercialization2022 to 2024 – Senior Vice President, People Strategy, Solutions & Services2024 to present – Executive Vice President, Chief Human Resources Officer |
| Karin ShanahanExecutive Vice President, Global Product Development & SupplyMember of the Leadership Team | 59 | 2013 to 2018 – Senior Vice President and Chief Operating Officer, Global Operations, Teva Pharmaceuticals2018 to 2022 – Senior Vice President, Global Biologics & Sterile Operations, Merck2022 to present – Executive Vice President, Global Product Development & Supply |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.